In patients with ccRCC demonstrating a sequenced alteration of SETD2 (i.e., frameshift), it can be presumed that the pathogenic SETD2 loss is biallelic due to the ubiquitous 3p loss in this tumor type. This evidence concerns the gene SETD2 and nonpapillary renal cell carcinoma.